Jadenu patents expiration

JADENU's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9283209 NOVARTIS PHARMS CORP Oral formulations of deferasirox
Nov, 2034

(11 years from now)

Jadenu is owned by Novartis Pharms Corp.

Jadenu contains Deferasirox.

Jadenu has a total of 1 drug patent out of which 0 drug patents have expired.

Jadenu was authorised for market use on 30 March, 2015.

Jadenu is available in tablet;oral dosage forms.

The generics of Jadenu are possible to be released after 21 November, 2034.

Drug Exclusivity Drug Exclusivity Expiration
M (M) Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 30 March, 2015

Treatment: NA


How can I launch a generic of JADENU before it's drug patent expiration?
More Information on Dosage

JADENU family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic